RNAZ
TransCode Therapeutics, Inc. (RNAZ) ESG Analysis Analysis (2026)
No material changes this month.
Environmental
RNAZ provides no disclosed emissions, energy, or waste metrics in the supplied data, leaving environmental peer comparison constrained versus more transparent healthcare peers.
The absence of reported R&D intensity and capital-efficiency detail limits assessment of resource-use discipline, while peers with fuller sustainability disclosure can demonstrate stronger environmental oversight.
No evidence in the provided metrics indicates material environmental liabilities, but the disclosure gap itself weakens relative positioning against peers with clearer climate and operational reporting.
Given the limited operating footprint implied by the data, environmental risk appears contained, yet RNAZ lacks the documented controls that would support a stronger peer-relative score.
Social
RNAZ shows no disclosed workforce, safety, or patient-access metrics in the provided data, which limits evidence of social performance relative to better-disclosing peers.
Zero stock-based compensation to revenue suggests limited dilution pressure, but it does not substitute for peer-level disclosure on employee alignment, retention, or culture.
The absence of controversy data prevents identifying major social weaknesses, yet peers with clearer human-capital reporting retain an informational advantage.
Overall social positioning is middling because RNAZ lacks the transparent social indicators that typically support stronger peer-relative confidence in stakeholder management.
Governance
RNAZ’s debt-to-equity ratio of 0.0047 and net debt-to-EBITDA of 0.18 indicate very low leverage, which generally supports governance discipline versus more levered peers.
Zero stock-based compensation to revenue suggests restrained equity dilution, a governance-positive signal relative to peers with heavier compensation-driven shareholder dilution.
However, the provided data do not include board independence, audit quality, or shareholder-rights metrics, limiting confidence in a stronger governance assessment.
On balance, RNAZ appears modestly better governed than peers on capital discipline, but incomplete disclosure prevents a higher relative score.
Overall Score
RNAZ’s ESG profile is moderate because low leverage and restrained dilution support governance, while limited disclosure across environmental and social metrics constrains peer-relative strength.
Score Driver: Governance Is The Main Support, But Incomplete ESG Disclosure Limits Relative Positioning.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on TransCode Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
